Skip to main content

Advertisement

Table 3 Bevacizumab plus chemotherapy versus chemotherapy

From: Targeted therapies in breast cancer: are heart and vessels also being targeted?

Study Treatment Line of therapy Number of patients Hypertension (grade 3 or 4) (%) CHF NYHA class III or IV (%) Thrombotic events (grade 3 or 4) (%)
Miller et al. [110] Capecitabine + bevacizumab versus capecitabine 1, 2, 3 462 G3: 17.9 versus 0.5 G4: 0 versus 0 G3: 2.2 versus 0
G4: 0.5 versus 0
Thrombotic event - general G3: 2.2. versus 0
G4: 0.5 versus 0
Miller et al. [58] Paclitaxel + bevacizumab versus paclitaxel 1 722 G3: 14.5 versus 0
G4: 0.3 versus 0
P = 0.001
LV dysfunction
G3: 0.8 versus 0
G4: 0 versus 0.3
P = NS
Cerebrovascular ischemia G3: 0.8 versus 0
G4: 1.1 versus 0
P = 0.02
Miles et al. (AVADO) [73] Docetaxel + bevacizumab (7.5 mg/kg) versus docetaxel + placebo 1 736 Grade 3 to 4: 0.8 versus 1.3 Grade 3 to 4: 1.2 versus 0 No G3-4 arterial events
  Docetaxel + bevacizumab (15 mg/kg) versus docetaxel+ placebo    Grade 3 to 4: 4.5 versus 1.3 Grade 3 to 4: 0 versus 0 Arterial events
G3: 0 versus 0
G4: 0.8 versus 0
Robert et al. (RIBBON-1) [60] Capecitabine plus bevacizumab versus capecitabine 1 605 Grade 3 to 4: 9.4 versus 1.0 LV dysfunction Grade 3 to 4: 1.0 versus 0.5 Venous events
4.8 versus 3.5
  Taxane + bvacizmaversus taxane   405 Grade 3 to 4: 8.9 versus 2.0 LV dysfunction
Grade 3 to 4: 2.0 versus 0
Venous events
2.0 versus 4.9
  Anthracycline + bevacizumb versus anthracycline   310 Grade 3 to 4: 10 versus 0 LV dysfunction
Grade 3 to 4: 2.9 versus 0
Venous events
2.9 versus 1.0
Brufsky et al.
(RIBBON-2) [72]
Chemotherapya + bevacizumab versus bevacizumab 2 684 Grade 3 to 4: 9 versus 0.5 LV dysfunction Grade 3 to 4: 0.9 versus 0 Arterial events
Grade 3 to 4: 0.7 versus 1.4
  1. aPrior to randomization, the investigators could choose among one of the following chemotherapy regimens: paclitaxel, nab-paclitaxel, gemcitabine, capecitabine and vinorelbine. CHF, congestive heart failure; G, grade; NS, not significant; NYHA, New York Heart Association.